文献
J-GLOBAL ID:202202288550620865
整理番号:22A0228920
BMX阻害剤,CHMFL-BMX-078はAKT経路の阻害を介してベムラフェニブに対するメラノーマの耐性を克服する【JST・京大機械翻訳】
CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway
著者 (15件):
Jiang ShiLong
(Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China)
,
Jiang ShiLong
(Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, PR China)
,
Jiang Ting
(Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China)
,
Huang HanXue
(Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China)
,
Huang HanXue
(Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, PR China)
,
Chen XiSha
(Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China)
,
Li LanYa
(Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China)
,
Wang ZhiBin
(Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China)
,
Wang ZhiBin
(Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, PR China)
,
Fei JiangFeng
(Sinocare Inc., Changsha, 410000, PR China)
,
Liu Chong
(Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China)
,
Liu Chong
(Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, PR China)
,
Liu ZhaoQian
(Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, PR China)
,
Liu ZhaoQian
(Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, 410078, PR China)
,
Cheng Yan
(Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China)
資料名:
Chemico-Biological Interactions
(Chemico-Biological Interactions)
巻:
351
ページ:
Null
発行年:
2022年
JST資料番号:
H0058B
ISSN:
0009-2797
CODEN:
CBINA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)